Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of HGI-001 Injection in Transfusion-Dependent Beta-Thalassemia
TCTR20240910004Phase 1Not yet recruiting
- Sponsor
- Hemogen HongKong Alpha Technology, Ltd
- Start
- Dec 2024
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of LentiHBBT87Q in beta thalassemia, sponsored by Hemogen HongKong Alpha Technology, Ltd. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
LentiHBBT87Q
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on TCTR20240910004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240910004.